Dr Jazieh Highlights the Prevalence of ALK+ NSCLC in the Middle East and North Africa

09/28/2020

Abdul Rahman Jazieh, MD, MPH, National Guard Health Affairs, Riyadh, Saudi Arabia, discusses a study on the prevalence of ALK+ NSCLC in the Middle East and North Africa and the importance of testing for it, presented at the ESMO 2020 Virtual Congress.

Recent News

News

First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer

11/04/2024

Stephanie Holland ;

According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...

According to results from a...

11/04/2024

Oncology

News

Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML

10/31/2024

Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...

Gilteritinib maintenance therapy...

10/31/2024

Oncology

News

Safety of Encorafenib Plus Binimetinib and Pembrolizumab for Advanced BRAF V600-Mutant Melanoma

10/31/2024

A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.

A safety lead-in for the...

10/31/2024

Oncology

News

Novel Next-Generation Sequencing Assay Proves Accurate in Detecting Mutations Among Patients Advanced HR-Positive, HER2-Negative Breast Cancer

10/31/2024

A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.

A multi-gene target panel NGS...

10/31/2024

Oncology

News

Fedratinib Demonstrates Promising Efficacy for Second-Line Treatment of Myelofibrosis

10/31/2024

According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.

According to a phase 3 trial,...

10/31/2024

Oncology

News

Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients With HR-Positive, HER2-Negative Breast Cancer

10/29/2024

Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.

Primary results from the...

10/29/2024

Oncology

FDA Approval

FDA Grants Accelerated Approval to Frontline Asciminib for Patients With Ph+ Chronic Myeloid Leukemia

10/29/2024

The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

The FDA granted accelerated...

10/29/2024

Oncology

News

Ramucirumab Added to Osimertinib Prolongs PFS for Patients With TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

10/29/2024

Results from the phase 2 RAMOSE study demonstrated that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival for patients with TKI-naive EGFR-mutated metastatic non-small cell lung cancer.

Results from the phase 2 RAMOSE...

10/29/2024

Oncology

News

Perioperative Chemoimmunotherapy Show Long-Term Benefit for Patients With Resectable Stage IIIA Non-Small Cell Lung Cancer

10/29/2024

According to updated 5-year results from the phase 2 NADIM trial, perioperative chemotherapy plus nivolumab sustains clinical benefit for patients with resectable stage IIIA non-small cell lung cancer.

According to updated 5-year...

10/29/2024

Oncology

News

Adjuvant Pembrolizumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma

10/24/2024

According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.

According to the phase 3...

10/24/2024

Oncology